Trials / Unknown
UnknownNCT06000709
Comparison Between Ultrasound-Guided Genicular Nerve Phenol Neurolysis and Intra-articular Steroid Injections
Randomized, Double-blinded, Comparison Between Ultrasound-Guided Genicular Nerve Phenol Neurolysis and Intra-articular Steroid Injections
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- University of Manitoba · Academic / Other
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Genicular nerve neurolysis (GN) constitutes a relatively novel technique, whereby different chemical compounds (i.e. alcohol, phenol) are injected in close proximity to the genicular nerves of the knee joint, with the intention to exert a neurolytic effect by denaturing proteins resulting in Wallerian degeneration distal to the lesion. Based on the preliminary evidence and considering the potential benefits of the technique, we hypothesized that ultrasound-guided genicular chemical neurolysis with phenol is superior in terms of pain relief at 3 months, when compared to intra-articular steroid (IAS) injection.
Detailed description
This study will allow us to determine if ultrasound-guided phenol genicular neurolys is superior to intra-articular steroid injection in terms of analgesia and functional outcomes, providing a more effective and long-lasting alternative for patients with chronic knee pain secondary to osteoarthritis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 6% aqueous phenol | 1.5 mL of aqueous phenol will be injected at each target genicular nerve under ultrasound guidance |
| DRUG | MethylPREDNISolone 40 MG | 40 mg of methylprednisolone diluted in 5 mL of 0.9% normal saline will be injected inside the knee joint capsule under ultrasound guidance |
| DRUG | Intraarticular Knee Placebo | Single injection 1.5 mL of 0.9% normal saline outside the knee joint capsule under ultrasound guidance |
| DRUG | Genicular Nerve Placebo | 1.5 mL of 0.9% normal saline will be injected subcutaneously at each target genicular nerve under ultrasound guidance |
Timeline
- Start date
- 2023-10-20
- Primary completion
- 2024-01-31
- Completion
- 2024-07-31
- First posted
- 2023-08-21
- Last updated
- 2023-10-10
Source: ClinicalTrials.gov record NCT06000709. Inclusion in this directory is not an endorsement.